Antibiotic resistance refers to bacteria becoming resistant to the drugs used to treat the infections they cause. Antibiotics are used to treat bacterial infections like pneumonia, urinary tract infections (UTIs), gonorrhea, and others. However, overuse and misuse of antibiotics has contributed to the growing problem of antibiotic resistance. Antibiotic resistance occurs through natural selection, whereby bacteria possessing genes that help them survive treatment outcompete and replace those bacteria killed off by the antibiotics. When bacteria evolve resistance, antibiotics become ineffective at the doses normally used to treat infections in humans.
The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 billion in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.
The global antibiotic resistance market is driven by the rising prevalence of infectious diseases coupled with the increasing resistance of microbes to existing antibiotics. Antibiotic-resistant infections are difficult to treat as standard antibiotics become ineffective. This has necessitated the need for development of novel anti-infectives. Antibiotic resistance occurs as a natural evolutionary response in bacteria to fight against strong selection pressure of antibiotics. However, this process has been rapidly accelerated due to overuse and misuse of existing antibiotics.
Key Takeaways
Key players operating in the Global Antibiotic Resistance Market Demand are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nemisis Biomedical Technologies and NEMESIS BIOSCIENCE LTD.
Key opportunities in the market include increasing clinical trials to develop novel anti-infectives, growing investment in R&D for new drug discovery, partnerships between companies and academic research institutions.
The major companies are focusing on expanding their product offerings and global footprint in regions such as North America, Europe, Asia Pacific and Rest of the world to tap into the lucrative opportunities.
Market Drivers
- Rising prevalence of infectious diseases propelled by the emergence of novel infectious strains and pandemics is a major factor contributing to the growth of antibiotic resistance. According to the WHO, antimicrobial resistance causes around 700,000 deaths each year globally.
- Excessive antibiotic use in livestock farming and aquaculture has contributed significantly to the emergence and spread of resistant bacteria.
Market Restraints
- Developing new antibiotics is a challenging, costly and time-consuming process. The clinical failure rate for new antibiotics is very high.
- Stringent regulatory environment delays the approval and market launch of new anti-infectives. This hinders faster development of effective treatment alternatives.
- Prudent use policies and antibiotic stewardship programs restrict the use and prescribing of newer broad-spectrum antibiotics, limiting growth opportunities.
Segment Analysis
The global antibiotic resistance market is dominated by the hospital acquired infections sub segment due to increase prevalence of drug resistant pathogens causing HAIs every year. These infections are difficult to treat as the pathogens have become resistant to existing last line of antibiotic treatments. According to WHO, Antibiotic resistant bacteria cause over 700,000 deaths every year globally due to HAIs. Most common HAIs include surgical site infections, urinary tract infections, pneumonia etc.
Global Analysis
North America accounts for the largest share in the global antibiotic resistance market led by U.S. due to high prevalence of drug resistant infections and rapidly aging population which is more prone to HAIs. The region is expected to witness significant growth during the forecast period due high awareness regarding antibiotic resistance and research initiatives taken by both public and private organizations in developing new resistant drugs. Asia Pacific is anticipated to grow at the fastest pace in the antibiotic resistance market, majorly driven by China, India and other southeast Asian countries. Factors such as increasing healthcare expenditure, large patient pool suffering from infectious diseases and growing R&D investments will contribute to the regional market growth.
Get more insights on Global Antibiotic Resistance Market
Comments
0 comment